Overslaan en naar de inhoud gaan

''As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce this step forward in this paediatric label expansion. This will enable us to treat attacks of patients of all ages living with HAE in the EU''

- Sijmen de Vries - CEO
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren